Soleno Therapeutics (SLNO) Total Debt (2013 - 2026)

Soleno Therapeutics (SLNO) has 6 years of Total Debt data on file, last reported at $49.9 million in Q1 2026.

• Total Debt for Q1 2026 came in at $49.9 million, changed 0.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.9 million (changed 0.07% YoY), and the FY2025 annual result was $49.9 million, changed 0.07% from the prior year.
• Total Debt was little changed at $49.9 million in Q1 2026 per SLNO's latest filing, from $49.9 million in the prior quarter.
• Over five years, Total Debt peaked at $49.9 million in Q1 2026 and troughed at $49.8 million in Q4 2024.
• A 3-year average of $49.8 million and a median of $49.8 million in 2025 frame the typical range for Total Debt.
• The sharpest annual moves came in 2025 and 2026: Total Debt gained 0.07% in 2025, then climbed 0.07% in 2026.
• A 3-year view of Total Debt shows it stood at $49.8 million in 2024, then gained by 0.07% to $49.9 million in 2025, then advanced by 0.02% to $49.9 million in 2026.
• Business Quant data shows SLNO's Total Debt at $49.9 million in Q1 2026, $49.9 million in Q4 2025, and $49.9 million in Q3 2025.